SynthesisPeerJ2025
Surgery, radiotherapy and endocrine therapy for oligometastatic prostate cancer efficacy: a systematic review and network meta-analysis.
Synthesis in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Risk factors for cognitive dysfunction in prostate cancer patients undergoing androgen deprivation therapy: a retrospective study.American journal of translational research · 2026Article
- Influence of m6A regulatory factor related to immune microenvironment on the prognosis of prostate cancer.Biomedical engineering online · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the treatment approach for metastatic prostate cancer has evolved, with early combination therapies increasingly being favored over androgen-deprivation therapy (ADT) alone. Despite the availability of various treatments, their relative effectiveness and safety trade-offs remain uncertain. Randomized controlled trials have explored a range of treatments for oligometastatic prostate cancer, but clear conclusions regarding their prognostic benefits and patient-centered outcomes have not been established. This network meta-analysis (NMA) aims to quantify the benefits of different treatments by analyzing data from a systematic search of Medline, EMBASE, and Cochrane databases, covering trials up to October 1, 2024. The primary outcomes evaluated in this study include overall survival (OS), progression-free survival (PFS), treatment-related adverse events (TRAEs), and quality of life (QoL). This study is registered with PROSPERO (CRD42022370203). We analyzed individual patient data from 13 eligible trials, involving a total of 2,524 patients. Our analysis revealed that ADT+ radiation therapy (RT) (hazard ratio (HR) = 0.39, 95% confidence interval (CI) [0.27-0.56]) and ADT+stereotactic body radiotherapy (SBRT) (HR = 0.35, 95% CI [0.21-0.58]) significantly improved progression-free survival (PFS) compared to ADT alone, while no treatment showed a significant overall survival (OS) benefit. Safety analysis revealed ADT monotherapy had the lowest risk of grade ≥3 adverse events (TRAEs), whereas ADT+abiraterone increased toxicity (OR = 1.54). Limited quality of life (QoL) data suggested ADT+RT may offer slight improvement (surface under the cumulative ranking curve (SUCRA) 74.3%). Most trials exhibited low bias risk, though heterogeneity and small sample sizes for some comparisons warrant cautious interpretation. These findings support ADT+RT/SBRT for PFS benefit but highlight the need for further research to optimize survival outcomes and treatment tolerability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.